問卷

TPIDB > Search Result

Search Result

篩選

List

28Cases

2025-09-30 - 2027-06-30

Phase II

Active
A phase 2, randomized, double-blind, placebo-controlled proof-of-concept trial was conducted to evaluate the efficacy and safety of EI-001 in patients with non-segmented vitiligo.
  • Condition/Disease

    • Percentage change of F-VASI relative to baseline in week 24

  • Test Drug

    EI-001

Participate Sites
2Sites

Recruiting2Sites

2021-08-31 - 2024-12-13

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

2023-10-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-06-10 - 2023-09-29

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-02-03 - 2022-12-16

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2025-09-10

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2022-10-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-10-13 - 2027-04-20

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-10-01 - 2024-07-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3